STOCK TITAN

Notifications

Limited Time Offer! Get Platinum at the Gold price until January 31, 2026!

Sign up now and unlock all premium features at an incredible discount.

Read more on the Pricing page

Lifecore Biomedical to Report Financial Results for First Quarter of Fiscal 2025 Prior to Market Open on October 4, 2024

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences earnings

Lifecore Biomedical (NASDAQ: LFCR), a fully integrated contract development and manufacturing organization (CDMO), has announced that it will release its financial results for the first quarter of fiscal year 2025 on Friday, October 4, 2024, before the market opens. The company will also host a webcast at 8:30 a.m. Eastern Time on the same day.

During the webcast, Lifecore's senior management team will discuss the quarterly financial results and provide an update on recent corporate developments. Investors and interested parties can access the live webcast or archived version through the Investor Events & Presentations page on Lifecore's website at https://ir.lifecore.com/events-presentations.

Loading...
Loading translation...

Positive

  • None.

Negative

  • None.

CHASKA, Minn., Oct. 03, 2024 (GLOBE NEWSWIRE) -- Lifecore Biomedical, Inc. (NASDAQ: LFCR) (“Lifecore”), a fully integrated contract development and manufacturing organization (“CDMO”), today announced that it will report financial results for the first quarter of fiscal year 2025 on Friday, October 4, 2024, prior to market open and will host a webcast at 8:30 a.m. Eastern Time. Members of Lifecore’s senior management team will discuss financial results for the first quarter and review recent corporate developments.

To listen to the live webcast, or access the archived webcast, please visit the Investor Events & Presentations page of Lifecore’s website at: https://ir.lifecore.com/events-presentations.

About Lifecore Biomedical

Lifecore Biomedical, Inc. (Nasdaq: LFCR) is a fully integrated contract development and manufacturing organization (CDMO) that offers highly differentiated capabilities in the development, fill and finish of sterile injectable pharmaceutical products in syringes, vials, and cartridges, including complex formulations. As a leading manufacturer of premium, injectable-grade hyaluronic acid, Lifecore brings more than 40 years of expertise as a partner for global and emerging biopharmaceutical and biotechnology companies across multiple therapeutic categories to bring their innovations to market. For more information about the company, visit Lifecore’s website at www.lifecore.com.


FAQ

When will Lifecore Biomedical (LFCR) report its Q1 FY2025 financial results?

Lifecore Biomedical (LFCR) will report its financial results for the first quarter of fiscal year 2025 on Friday, October 4, 2024, before the market opens.

What time is Lifecore Biomedical's (LFCR) Q1 FY2025 earnings webcast scheduled for?

Lifecore Biomedical's (LFCR) Q1 FY2025 earnings webcast is scheduled for 8:30 a.m. Eastern Time on Friday, October 4, 2024.

Where can I access Lifecore Biomedical's (LFCR) Q1 FY2025 earnings webcast?

You can access Lifecore Biomedical's (LFCR) Q1 FY2025 earnings webcast through the Investor Events & Presentations page on the company's website at https://ir.lifecore.com/events-presentations.

What will be discussed during Lifecore Biomedical's (LFCR) Q1 FY2025 earnings call?

During Lifecore Biomedical's (LFCR) Q1 FY2025 earnings call, the senior management team will discuss the quarterly financial results and review recent corporate developments.
Lifecore Biomedical Inc

NASDAQ:LFCR

LFCR Rankings

LFCR Latest News

LFCR Latest SEC Filings

LFCR Stock Data

295.98M
36.71M
1.99%
76.48%
6.93%
Drug Manufacturers - Specialty & Generic
Pharmaceutical Preparations
Link
United States
CHASKA